ClinicalTrials.gg
CompletedNCT02205255FarmEcUpdated Apr 8, 2020

BACE Trial Substudy 2 - FarmEc Substudy

A Phase 3 interventional study of Azithromycin and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Wim Janssens. Completed at 20 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Wim Janssens · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Azithromycin · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
5th of 17
350 · median 92
Started
2014
with 2 others
Phase 3
6 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
3 of 17
Wim Janssens

Among the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by planned enrollment, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azithromycin

Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

A second sub-analysis of the BACE trial will include a detailed cost-effectiveness study.

Read the detailed description

Our multicenter randomized trial executed in one country will provide an excellent tool for more precise health economic assessments. In a first approach, rough estimates on savings of direct costs in the entire study cohort will be made by taking into account the Flemish average costs for a single hospitalization day at a respiratory ward, for a day at intensive care, for an emergency visit, for a home physician contact and for an antibiotic-steroid course. A more detailed cost-effectiveness and cost-utility analysis at 3 and 9 months interval will only be performed in case significant clinical benefits are found in favor of the active treatment.

For this purpose medical resource use data will be collected retrospectively via hospital invoices (direct costs including drugs, physician visits, laboratory tests, technical exams, medical imaging, hospital stay) but also prospectively via patient diaries, to cover direct and indirect costs during the entire outpatient period, and will be linked to EQ5D scores.

Patient will have to give informed consent that additional to the clinical evaluation, invoices will be collected. However, individual patients can still opt out for these analyses (sub-study) and only participate in the medical intervention study (main study).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • AECOPD
  • Chronic Obstructive Pulmonary Disease
  • Acute exacerbation
  • Hospitalization
  • Azithromycin
  • Macrolides
  • Randomized Controlled Trial
  • Placebo
  • Economic Impact
  • Cost-effectiveness
  • EQ5D
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of by medical doctor (based on clinical history OR pulmonary function test)
  • Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years, etc.)
  • Current hospitalization for potential infectious AECOPD treated with standard therapy
  • History of at least one exacerbation during the last year (prior to the current hospital admission) for which systemic and/or antibiotics were taken
  • at admission

Exclusion criteria

Exclusion Criteria:

  • Mechanical or non-invasive ventilation at moment of randomization (D1)
  • Long on (QTc > 450msec for males or > 470msec for females)
  • History of life-threatening arrhythmias
  • Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug
  • Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission
  • Drugs with high risk for long QT interval and torsade de pointes (amiodarone, flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)
  • Documented uncorrected severe hypokalemia (K+ \< 3.0 mmol/L) or hypomagnesemia (Mg2+ \< 0.5 mmol/L)
  • Chronic systemic (> 4 mg methylprednisolone /day for ≥ 2 months)
  • Actual use of macrolides for at least 2 weeks
  • Allergy to macrolides
  • Active cancer treatment
  • \< 3 months
  • Pregnant or breast-feeding subjects. Woman of must have a pregnancy test performed and a negative result must be documented before start of treatment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Azithromycin

    N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days

    Drug: Azithromycin

  • Placebo comparator
    Placebo

    N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days

    Drug: Placebo

Interventions

  • From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days

    Also known as: Azitromcyine CF, ATC code: J01FA10

  • DrugPlacebo

    Also known as: Inactive substance

06

What researchers measure

Primary outcomes

  1. Total cost (direct and Indirect cost) during the entire study participation

    Direct costs (including drugs, physician visits, laboratory tests, technical exams, medical imaging, hospital stay) will be assessed by collecting the medical resource use data retrospectively via hospital invoices and prospectively via patient diaries. Indirect costs (relating to time, convenience, and transportation) will be assessed by collecting the medical resource use data prospectively via patient diaries. This outcome measure will also be analysed in following subgroups: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * Former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \< 60 years vs age 60 - 70 years vs age \> 70 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: At 3 month interval

Secondary outcomes

  1. Total cost (direct and Indirect cost) during the entire study participation

    Direct costs (including drugs, physician visits, laboratory tests, technical exams, medical imaging, hospital stay) will be assessed by collecting the medical resource use data retrospectively via hospital invoices and prospectively via patient diaries. Indirect costs (relating to time, convenience, and transportation) will be assessed by collecting the medical resource use data prospectively via patient diaries. This outcome measure will also be analysed in following subgroups: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * Former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \< 60 years vs age 60 - 70 years vs age \> 70 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: At 9 month interval

07

Study locations

20 sites
  • UZ Brussel
    Brussel, Brussel Hoofdstedelijk Gewest 1090, Belgium
  • St. Pieterziekenhuis
    Brussel, Brussels Hoofdstedelijk Gewest 1000, Belgium
  • ZNA Middelheim
    Antwerpen, Vlaanderen 2020, Belgium
  • St. Augustinus Ziekenhuis
    Antwerpen, Vlaanderen 2610, Belgium
  • Imelda Ziekenhuis
    Bonheiden, Vlaanderen 2820, Belgium
  • St. Jan Brugge Ziekenhuis
    Brugge, Vlaanderen 8000, Belgium
  • Maria Middelaresziekenhuis
    Gent, Vlaanderen 9000, Belgium
  • UZ Gent
    Gent, Vlaanderen 9000, Belgium
  • Jessa Ziekenhuis
    Hasselt, Vlaanderen 3500, Belgium
  • AZ Groeninge Ziekenhuis
    Kortrijk, Vlaanderen 8500, Belgium
  • UZ Gasthuisberg
    Leuven, Vlaanderen 3000, Belgium
  • Heilig Hart Ziekenhuis
    Roeselare, Vlaanderen 8800, Belgium
  • St. Andriesziekenhuis
    Tielt, Vlaanderen 8700, Belgium
  • CHU Charleroi
    Charleroi, Wallonië 6110, Belgium
  • Grand Hôpital de Charleroi
    Gilly, Wallonië 6060, Belgium
  • CHU Liège
    Liège, Wallonië 4000, Belgium
  • CHU Mont-Godinne
    Yvoir, Wallonië 5530, Belgium
  • Onze-Lieve-Vrouwziekenhuis
    Aalst, 9300, Belgium
  • Clinique Reine Astrid
    Malmedy, 4960, Belgium
  • Clinique Sainte-Elisabeth
    Namur, 5000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Apr 2018, 44 months.

Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's 44 months is close to that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2014
First posted
Jul 31, 2014
StartActual
Aug 1, 2014
Primary completionActual
Apr 2018
CompletionActual
Apr 2020
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02205255
Lead sponsor
Wim Janssens
Responsible party
Wim Janssens (MD. PhD, KU Leuven) — Sponsor-investigator
First posted
Jul 31, 2014
Start date
Aug 1, 2014
Primary completion
Apr 2018
Completion
Apr 2020
Last update
Apr 8, 2020

Study contacts

Wim Janssens, MD PhD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azithromycin

Start the discussion